PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 9:55 AM ET

Sponsor Check › Person

TK
No photo found yet (own website and image search run after this page is viewed)

Tomas Kiselak

Named as an officer, director or promoter on SEC Form D filings · PA, MA, CO, TX · Oct 6, 2016 → Oct 8, 2026

20deals (issuers)
$2.51Breported sold
370investors
50Form D filings
2016–2026years on file
Follow this personLook further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:16 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

Tomas Kiselak is listed as an executive officer, director, and promoter on 50 SEC Form D filings by 20 issuers between Oct 2016 and Oct 2026. Largest by amount reported sold: Fairmount Healthcare Feeder Fund II L.P. (West Conshohocken, PA — pooled investment fund — 2019–2026; $1.07B reported sold to 51 investors), Fairmount Healthcare Fund II L.P. (West Conshohocken, PA — pooled investment fund — 2019–2026; $667M reported sold to 52 investors), Spyre Therapeutics, Inc. (Waltham, MA — biotechnology — 2023; $210M reported sold to 54 investors), Zenas BioPharma, Inc. (Waltham, MA — biotechnology — 2022–2024; $200.1M reported sold to 26 investors), Dianthus Therapeutics, Inc. (Waltham, MA — biotechnology — 2021–2022; $100M reported sold to 22 investors) and 15 more (all listed below).

What this means That is a lot of deals — 20 separate companies raised money with this person listed as executive officer, director, and promoter, over about 10 years. Across those companies the filings report $2.51B sold in total.

Listed alongside Peter Harwin (43 shared filings), Fairmount Funds Management LLC (21 shared filings, management entity), Fairmount Healthcare Fund II GP LLC (12 shared filings, management entity), Investment Manager Fairmount Funds Management LLC (10 shared filings, management entity), Leon O. Moulder, Jr. (7 shared filings) and 54 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Tomas. Each name links to their own page.

The issuers belong to 2 sponsor groups: Fairmount Healthcare (15 issuers, $1.85B reported sold, 2016–2026) and Miragen Therapeutics (2 issuers, $131.7M reported sold, 2009–2020).

What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CO, CT, DC, DE, FINRA, FL, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, WA, WI, WV, WY) — 2 court cases matching the name, 2 SEC releases, 1 bankruptcy case matching the name listed in Key records below.

What this means 5 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.

We compared 50 public filings for Tomas Kiselak and found 18 differences, 4 worth asking the sponsor about: 2 court cases name Tomas Kiselak; Investor count went down between filings; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for Tomas Kiselak has not run yet — it is joining a line of 43,547 names; searches run around the clock at the hosts' allowed rate. Searched so far: 641 names.

Community comments are quoted as written by their authors. Sources searched: Bing (site:reddit.com / site:biggerpockets.com) and Reddit's own search, plus DuckDuckGo/Brave/BiggerPockets search when they are answering.

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

2 cases: 1 closed (disposition not in docket feed), 1 judgment

Securities and Exchange Commission v. Kiselak Capital Group LLC closed
District Court, C.D. California · No. 5:11-mc-00021 · Filed Aug 25, 2011 · Closed Aug 25, 2011
Role of Kiselak Capital Group LLC: Defendant · Outcome: Terminated 2011-08-25 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same rare surname (3 people in Form D filings, 4 federal dockets); surname only in the caption; court in CA (not a filing state)
Securities and Exchange Commission v. Kiselak Capital Group LLC judgment
District Court, N.D. Texas · No. 4:09-cv-00256 · Filed May 11, 2009 · Closed Oct 15, 2009 · Nature of suit: 850 Other Statutes: Securities/Commodities/Exchange · Cause: 15:77 Securities
Role of Kiselak Capital Group LLC: Defendant · Outcome: Terminated 2009-10-15 — FJC Integrated Database disposition: Judgment on motion before trial; judgment for plaintiff Docket on CourtListener ↗
same rare surname (3 people in Form D filings, 4 federal dockets); surname only in the caption; court in the person's filing state (TX)
What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:16 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

2 SEC releases

Michael J. Kiselak Administrative proceeding
SEC · Jun 16, 2009 · Parties as named in the release: Michael J. Kiselak Read the release ↗
same rare surname (3 people in Form D filings); different first name (michael)
Kiselak Capital Group, LLC et al Litigation release
SEC · May 11, 2009 · Parties as named in the release: Kiselak Capital Group, LLC et al Read the release ↗
same rare surname (3 people in Form D filings); surname inside a company name in the title
What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Tomas Kiselak..

State securities regulators: Securities regulators searched (64,910 actions): FINRA (38,350 actions, 1995–2026), NASAA (31 actions, 2000–2026; listing starts 1997), AK Division of Banking and Securities (273 actions, 1971–2025), AL Securities Commission (880 actions, 2001–2026), AR Securities Department (1,305 actions, 1998–2026), AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), CO Division of Securities (731 actions, 2001–2026; older years from the Internet Archive (snapshot of 2026-05-02)), CT Department of Banking Securities Division (940 actions, 2006–2026; older years from the Internet Archive (snapshot of 2026-04-22)), DC DISB Securities Bureau (25 actions, 2012–2026), DE DOJ Investor Protection Unit (257 actions, 1987–2026), FL Office of Financial Regulation (49 actions, 2018–2026), GA Secretary of State Securities Division (65 actions, 2015–2026; listing starts 2012), HI DCCA Securities Enforcement Branch (26 actions, 2012–2026), ID Department of Finance Securities Bureau (663 actions, 1994–2026), IL Secretary of State Securities Department (4,122 actions, 2003–2023), KS Insurance Department Securities Division (58 actions), KY Department of Financial Institutions (342 actions, 2005–2026), LA Office of Financial Institutions Securities Division (13 actions, 2010–2025; listing starts 2008), MA Secretary of the Commonwealth Securities Division (125 actions, 2012–2025; live site blocks automated access — loaded from the Internet Archive snapshot of 2026-02-04), MD Attorney General Securities Division (1,054 actions, 2004–2026), ME Office of Securities (539 actions, 2000–2026), MI LARA Corporations, Securities & Commercial Licensing Bureau (201 actions), MO Secretary of State Securities Division (919 actions, 1998–2026), MS Secretary of State Securities Division (209 actions, 1995–2026), MT Commissioner of Securities and Insurance (597 actions, 2000–2026), NC Secretary of State Securities Division (265 actions, 2004–2024), ND Securities Department (711 actions, 1990–2026; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2026-01-06), NH Bureau of Securities Regulation (402 actions, 2002–2026), NM Regulation and Licensing Department Securities Division (90 actions, 2010–2025), NV Secretary of State Securities Division (118 actions, 2018–2026), NY Attorney General Investor Protection Bureau (44 actions, 2012–2026), OH Division of Securities (327 actions, 1993–2006), OK Department of Securities (2,531 actions, 1998–2026), OR Division of Financial Regulation (589 actions, 1988–2026), PA Department of Banking and Securities (1,448 actions, 2008–2024; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2024-08-09), RI DBR Securities Division (98 actions, 2005–2025), SC Attorney General Securities Division (540 actions, 2006–2026), SD Division of Insurance – Securities Regulation (106 actions, 2017–2026), TN Department of Commerce and Insurance Securities Division (405 actions, 1992–2026), TX State Securities Board (936 actions, 1999–2026), UT Division of Securities (772 actions, 2000–2026; older years from the Internet Archive (snapshot of 2010-05-27)), VT DFR Securities Division (137 actions, 2010–2026), WA DFI (2,039 actions, 2001–2026), WI DFI Division of Securities (1,072 actions, 1998–2026), WV Securities Commission (State Auditor) (64 actions), WY Secretary of State Compliance Division (6 actions, 2016–2024) — last crawled Oct 24, 2026, 8:48 AM ET. No machine-readable public listing today for IA, IN, MN, NE, NJ, VA (see docs/state-regulators.md).

3. Bankruptcies

1 case: 1 closed (disposition not in docket feed)

David Scott Kiselak closed
United States Bankruptcy Court, N.D. Texas · No. 04-33789 · Filed Apr 4, 2004 · Closed Apr 4, 2005
Role of David Scott Kiselak: Debtor · Outcome: Case closed 2005-04-04 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same rare surname (3 people in Form D filings, 4 federal dockets); different first name (scott); court in the person's filing state (TX)
What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:16 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

18 differences found between the filings for Tomas Kiselak — 4 worth asking about (compared 50 filings on Oct 24, 2026)

Worth asking · May 11, 2009 – Aug 25, 2011

2 court cases name Tomas Kiselak — 2 as defendant

By role: defendant in 2. Newest: "Securities and Exchange Commission v. Kiselak Capital Group LLC" (District Court, C.D. California, Aug 25, 2011); "Securities and Exchange Commission v. Kiselak Capital Group LLC" (District Court, N.D. Texas, May 11, 2009). Some of these are name matches with a match estimate below 95% — check each docket.

What this means Several court cases name this subject. Some are routine business suits. Ask what each was about and how it ended.

Docket · Securities and Exchange Commission v. Kiselak Capital Group LLC ↗Docket · Securities and Exchange Commission v. Kiselak Capital Group LLC ↗
Sources
Worth asking · Nov 14, 2018 – Nov 7, 2019

Investor count went down between filings — Fairmount Healthcare Fund L.P.

The Nov 14, 2018 filing reports 65 investors; the Nov 7, 2019 Form D/A reports 43 investors.

What this means Investor counts normally only grow. A smaller number can mean investors left or were refunded, or a count was corrected. Ask the sponsor what happened.

Form D/A (earlier) · Nov 14, 2018 ↗Form D/A (later) · Nov 7, 2019 ↗Fairmount Healthcare Fund L.P. — PartnerFacts page ↗
Sources
Worth asking · Nov 14, 2018 – Nov 7, 2019

Investor count went down between filings — Fairmount Healthcare Feeder Fund Ltd.

The Nov 14, 2018 filing reports 8 investors; the Nov 7, 2019 Form D/A reports 6 investors.

What this means Investor counts normally only grow. A smaller number can mean investors left or were refunded, or a count was corrected. Ask the sponsor what happened.

Form D/A (earlier) · Nov 14, 2018 ↗Form D/A (later) · Nov 7, 2019 ↗Fairmount Healthcare Feeder Fund Ltd. — PartnerFacts page ↗
Sources
Note · Dec 13, 2018

Tomas Kiselak appears on 1 deal that stopped filing before reaching its target

Viridian, LLC (last filing Dec 13, 2018; $1,150,000 sold of $3,000,000). Each has no filing in more than two years and reported under half its target sold.

What this means An issuer whose last filing is more than two years old and reported under half its target sold. The raise may have closed early or quietly stopped. Ask what happened to each.

Viridian, LLC — PartnerFacts page ↗
Sources
Note · Dec 11, 2023 – Dec 27, 2023

Form D filed 16 days after the first sale — Spyre Therapeutics, Inc.

The filing says the first sale was Dec 11, 2023. The Form D was filed Dec 27, 2023 — 16 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 1 days past that.

What this means A late notice is common and carries no penalty by itself. It is worth asking the sponsor why the paperwork lagged.

Form D · Dec 27, 2023 ↗Spyre Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Jul 10, 2023 – Aug 21, 2023

Form D filed 42 days after the first sale — Fairmount Healthcare Co-Invest II L.P.

The filing says the first sale was Jul 10, 2023. The Form D was filed Aug 21, 2023 — 42 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 27 days past that.

What this means A late notice is common and carries no penalty by itself. It is worth asking the sponsor why the paperwork lagged.

Form D · Aug 21, 2023 ↗Fairmount Healthcare Co-Invest II L.P. — PartnerFacts page ↗
Sources
Note · Jan 30, 2019 – Mar 5, 2019

Form D filed 34 days after the first sale — Fairmount Healthcare Feeder Fund II L.P.

The filing says the first sale was Jan 30, 2019. The Form D was filed Mar 5, 2019 — 34 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 19 days past that.

What this means A late notice is common and carries no penalty by itself. It is worth asking the sponsor why the paperwork lagged.

Form D · Mar 5, 2019 ↗Fairmount Healthcare Feeder Fund II L.P. — PartnerFacts page ↗
Sources
Note · Oct 14, 2016 – Jun 3, 2024

8 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — Interius BioTherapeutics, Inc. (latest filing Jun 3, 2024) · No amendment in the last 12 months on an offering that may still be open — Dianthus Therapeutics, Inc. (latest filing Jun 7, 2021) · No amendment in the last 12 months on an offering that may still be open — Interius BioTherapeutics, Inc. (latest filing May 27, 2021) · No amendment in the last 12 months on an offering that may still be open — Fairmount Healthcare Fund L.P. (latest filing Oct 27, 2020) · No amendment in the last 12 months on an offering that may still be open — Fairmount Healthcare Feeder Fund Ltd. (latest filing Oct 27, 2020) · and 3 more

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Form D · Jun 3, 2024 ↗Interius BioTherapeutics, Inc. — PartnerFacts page ↗Form D · Jun 7, 2021 ↗Dianthus Therapeutics, Inc. — PartnerFacts page ↗
Sources
Worth asking · Dec 11, 2018 – Aug 18, 2020

Tomas Kiselak is no longer listed on the Aug 18, 2020 amendment — Quellis Biosciences, Inc.

Tomas Kiselak appears on the Dec 11, 2018 Form D (executive officer, director) but not on the Aug 18, 2020 Form D/A for the same offering.

What this means People leave, and the issuer must list only current officers, directors and promoters. It is still worth asking why this person left and who replaced them.

Form D · Dec 11, 2018 ↗Form D/A · Aug 18, 2020 ↗Tomas Kiselak — PartnerFacts page ↗Quellis Biosciences, Inc. — PartnerFacts page ↗
Sources
Note · May 5, 2023 – Sep 18, 2023

Tomas Kiselak's role changed at Fairmount Healthcare Feeder Fund II L.P.: executive officer, director, promoter → executive officer, promoter

The May 5, 2023 filing lists Tomas Kiselak as executive officer, director, promoter; the Sep 18, 2023 Form D/A lists executive officer, promoter.

What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.

Form D/A · May 5, 2023 ↗Form D/A · Sep 18, 2023 ↗Tomas Kiselak — PartnerFacts page ↗Fairmount Healthcare Feeder Fund II L.P. — PartnerFacts page ↗
Sources
Note · Feb 28, 2020 – May 19, 2021

Tomas Kiselak's role changed at Fairmount Healthcare Feeder Fund II L.P.: executive officer, promoter → executive officer, director, promoter

The Feb 28, 2020 filing lists Tomas Kiselak as executive officer, promoter; the May 19, 2021 Form D/A lists executive officer, director, promoter.

What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.

Form D/A · Feb 28, 2020 ↗Form D/A · May 19, 2021 ↗Tomas Kiselak — PartnerFacts page ↗Fairmount Healthcare Feeder Fund II L.P. — PartnerFacts page ↗
Sources
Note · Dec 11, 2018 – Aug 18, 2020

Offering amount changed between filings — Quellis Biosciences, Inc.

The Dec 11, 2018 filing says $18,518,047 offered; the Aug 18, 2020 Form D/A says $18,519,814.

What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.

Form D (earlier) · Dec 11, 2018 ↗Form D/A (later) · Aug 18, 2020 ↗Quellis Biosciences, Inc. — PartnerFacts page ↗
Sources
Note · May 5, 2023 – Jun 3, 2024

Minimum investment changed between filings — Fairmount Healthcare Fund II L.P.

The May 5, 2023 filing lists a minimum of $1,000,000; the Jun 3, 2024 Form D/A lists $1.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Form D/A (earlier) · May 5, 2023 ↗Form D/A (later) · Jun 3, 2024 ↗Fairmount Healthcare Fund II L.P. — PartnerFacts page ↗
Sources
Note · May 5, 2023 – Sep 18, 2023

Minimum investment changed between filings — Fairmount Healthcare Feeder Fund II L.P.

The May 5, 2023 filing lists a minimum of $1,000,000; the Sep 18, 2023 Form D/A lists $1.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Form D/A (earlier) · May 5, 2023 ↗Form D/A (later) · Sep 18, 2023 ↗Fairmount Healthcare Feeder Fund II L.P. — PartnerFacts page ↗
Sources
Note · Nov 15, 2022

Formed in 2023 per the latest filing, but activity is dated 2022 — Zenas BioPharma, Inc.

The issuer's latest filing says it was formed in 2023. The Nov 15, 2022 filing says the first sale was Nov 2, 2022 — before that year.

What this means A company cannot sell before it exists, so one of the two dates is likely a typo on the form. Ask the sponsor for the formation document.

Form D · Nov 15, 2022 ↗Zenas BioPharma, Inc. — PartnerFacts page ↗
Sources
Note · Mar 5, 2019

Formed in 2023 per the latest filing, but activity is dated 2019 — Fairmount Healthcare Feeder Fund II L.P.

The issuer's latest filing says it was formed in 2023. The Mar 5, 2019 filing says the first sale was Jan 30, 2019 — before that year.

What this means A company cannot sell before it exists, so one of the two dates is likely a typo on the form. Ask the sponsor for the formation document.

Form D · Mar 5, 2019 ↗Fairmount Healthcare Feeder Fund II L.P. — PartnerFacts page ↗
Sources
Note · Dec 11, 2018 – Dec 27, 2023

4 address changes between filings

Address moved from Austin, TX to Waltham, MA — Spyre Therapeutics, Inc. · Address moved from Philadelphia, PA to West Conshohocken, PA — Fairmount Healthcare Feeder Fund II L.P. · Address moved from Philadelphia, PA to West Conshohocken, PA — Fairmount Healthcare Fund II L.P. · Address moved from Philadelphia, PA to Waltham, MA — Quellis Biosciences, Inc.

What this means Businesses move. If you were told one city and the forms say another, ask which is current.

Form D · Jul 6, 2023 ↗Form D · Dec 27, 2023 ↗Spyre Therapeutics, Inc. — PartnerFacts page ↗Form D/A · May 19, 2022 ↗
Sources
Note · Oct 6, 2016 – Oct 8, 2026

Tomas Kiselak is listed with 4 different address states: PA, MA, CO, TX

PA on 41 filings (Oct 6, 2016 to Oct 8, 2026); MA on 7 filings (May 8, 2020 to May 14, 2024); CO on 1 filing (Nov 6, 2020); TX on 1 filing (Jul 6, 2023).

What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.

Form D · Oct 6, 2016 ↗Form D · May 8, 2020 ↗Form D · Nov 6, 2020 ↗Form D · Jul 6, 2023 ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

1 of 27 offerings reports sales commissions totalling $3,000,000; 3 report finder's fees totalling $27,949,881; 0 report proceeds to related persons.

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Oct 8, 2026 D
Fairmount Healthcare Co-Invest VII L.P.
File 021-600543
$0$0$0None listed on this filingEDGAR ↗
May 29, 2026 D/A
Fairmount Healthcare Feeder Fund II L.P.
File 021-334107
$0$0$0None listed on this filingEDGAR ↗
May 29, 2026 D/A
Fairmount Healthcare Fund II L.P.
File 021-334111
$0$0$0None listed on this filingEDGAR ↗
Apr 3, 2026 D
Paragon Laboratories L.P.
File 021-579089
$0$0$0None listed on this filingEDGAR ↗
Mar 31, 2026 D
Fairmount Healthcare Co-Invest VI L.P.
File 021-578593
$0$0$0None listed on this filingEDGAR ↗
Nov 5, 2025 D
Fairmount Healthcare Co-Invest V L.P.
File 021-563202
$0$0$0None listed on this filingEDGAR ↗
Oct 31, 2024 D
Fairmount Healthcare Co-Invest IV L.P.
File 021-528380
$0$0$0None listed on this filingEDGAR ↗
Jun 3, 2024 D
Interius BioTherapeutics, Inc.
File 021-514940
$0$0$0None listed on this filingEDGAR ↗
May 14, 2024 D
Zenas BioPharma, Inc.
File 021-513274
$0$0$0None listed on this filingEDGAR ↗
Mar 29, 2024 D
Fairmount Healthcare Co-Invest III L.P.
File 021-509054
$0$0$0None listed on this filingEDGAR ↗
Dec 27, 2023 D
Spyre Therapeutics, Inc.
File 021-500772
$0$10,800,000$0Jefferies LLC BrokerCheck CRD 2347 ↗
Cowen and Company, LLC BrokerCheck CRD 7616 ↗
Stifel, Nicolaus & Company, Incorporated BrokerCheck CRD 793 ↗
Guggenheim Securities, LLC BrokerCheck CRD 40638 ↗
LifeSci Capital LLC BrokerCheck CRD 168404 ↗		EDGAR ↗
Oct 20, 2023 D
Interius BioTherapeutics, Inc.
File 021-495284
$0$0$0None listed on this filingEDGAR ↗
Aug 21, 2023 D
Fairmount Healthcare Co-Invest II L.P.
File 021-490287
$0$0$0None listed on this filingEDGAR ↗
Jul 6, 2023 D
Spyre Therapeutics, Inc.
File 021-486102
$0$12,600,015$0Jefferies LLC BrokerCheck CRD 2347 ↗
Cowen and Company, LLC BrokerCheck CRD 7616 ↗
Stifel, Nicolaus & Company, Incorporated BrokerCheck CRD 793 ↗
Guggenheim Securities, LLC BrokerCheck CRD 40638 ↗		EDGAR ↗
Jun 30, 2023 D
Fairmount Healthcare Co-Invest L.P.
File 021-485732
$0$0$0None listed on this filingEDGAR ↗
Nov 15, 2022 D
Zenas BioPharma, Inc.
File 021-464885
$0$0$0None listed on this filingEDGAR ↗
Apr 21, 2022 D
Dianthus Therapeutics, Inc.
File 021-442826
$3,000,000$0$0Jefferies LLC BrokerCheck CRD 2347 ↗
via Jefferies LLC (CRD 2347 ↗)
EDGAR ↗
Jun 7, 2021 D
Dianthus Therapeutics, Inc.
File 021-401968
$0$0$0None listed on this filingEDGAR ↗
May 27, 2021 D
Interius BioTherapeutics, Inc.
File 021-400861
$0$0$0None listed on this filingEDGAR ↗
Nov 6, 2020 D
MIRAGEN THERAPEUTICS, INC.
File 021-379997
$0$4,549,866$0Jefferies LLC BrokerCheck CRD 2347 ↗
JMP Securities LLC BrokerCheck CRD 22208 ↗		EDGAR ↗
Oct 27, 2020 D/A
Fairmount Healthcare Feeder Fund Ltd.
File 021-271986
$0$0$0None listed on this filingEDGAR ↗
Oct 27, 2020 D/A
Fairmount Healthcare Fund L.P.
File 021-271988
$0$0$0None listed on this filingEDGAR ↗
Sep 29, 2020 D
Viridian Therapeutics, Inc.
File 021-376545
$0$0$0None listed on this filingEDGAR ↗
May 8, 2020 D
Viridian Therapeutics, Inc.
File 021-366547
$0$0$0None listed on this filingEDGAR ↗
Dec 13, 2018 D
Viridian, LLC
File 021-327913
$0$0$0None listed on this filingEDGAR ↗
Dec 11, 2018 D
Quellis Biosciences, Inc.
File 021-327586
$0$0$0None listed on this filingEDGAR ↗
Jun 1, 2018 D
Quellis Biosciences, Inc.
File 021-313711
$0$0$0None listed on this filingEDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 20

Every issuer that named Tomas Kiselak on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

FH
Pooled Investment Fund · group: Fairmount Healthcare

Fairmount Healthcare Co-Invest VII L.P.

West Conshohocken, PA · Oct 8, 2026
  • Oct 8, 2026 · D · $0 sold of Indefinite · 0 investors · min. $1 · role: Executive Officer, Promoter (Managing Member of the Member of the General Partner and Investment Manager of the Issuer) EDGAR ↗

No sales reported yet as of the latest filing. Tomas is listed as executive officer, promoter.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FH
Pooled Investment Fund · group: Fairmount Healthcare

Fairmount Healthcare Feeder Fund II L.P.

West Conshohocken, PA · Mar 5, 2019 → May 29, 2026 · 9 filings
  • May 29, 2026 · D/A · $1,074,275,867 sold of Indefinite · 51 investors · min. $1 · role: Executive Officer, Promoter (Managing Member of the General Partner and Investment Manager) EDGAR ↗
  • May 29, 2025 · D/A · $944,859,587 sold of Indefinite · 36 investors · min. $1 · role: Executive Officer, Promoter (Managing Member of the General Partner and Investment Manager) EDGAR ↗
  • Jun 3, 2024 · D/A · $673,309,587 sold of Indefinite · 23 investors · min. $1 · role: Executive Officer, Promoter (Managing Member of the General Partner and Investment Manager) EDGAR ↗
  • Sep 18, 2023 · D/A · $517,390,000 sold of Indefinite · 20 investors · min. $1 · role: Executive Officer, Promoter (Managing Member of the General Partner and Investment Manager) EDGAR ↗
  • May 5, 2023 · D/A · $377,390,000 sold of Indefinite · 19 investors · min. $1,000,000 · role: Executive Officer, Director, Promoter (Managing Member of Investment Manager and Director of the Issuer) EDGAR ↗
  • May 19, 2022 · D/A · $345,640,000 sold of Indefinite · 18 investors · min. $1,000,000 · role: Executive Officer, Director, Promoter (Managing Member of Investment Manager and Director of the Issuer) EDGAR ↗
  • May 19, 2021 · D/A · $233,350,000 sold of Indefinite · 15 investors · min. $1,000,000 · role: Executive Officer, Director, Promoter (Managing Member of Investment Manager and Director of the Issuer) EDGAR ↗
  • Feb 28, 2020 · D/A · $105,000,000 sold of Indefinite · 3 investors · min. $1,000,000 · role: Executive Officer, Promoter EDGAR ↗
  • Mar 5, 2019 · D · $5,000,000 sold of Indefinite · 1 investors · min. $1,000,000 · role: Executive Officer, Promoter EDGAR ↗

Raised $1.07B from 51 investors as of the latest filing. Tomas is listed as executive officer, promoter, director on 9 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FH
Pooled Investment Fund · group: Fairmount Healthcare

Fairmount Healthcare Fund II L.P.

West Conshohocken, PA · Mar 5, 2019 → May 29, 2026 · 8 filings
  • May 29, 2026 · D/A · $667,035,598 sold of Indefinite · 52 investors · min. $1 · role: Executive Officer, Promoter (Managing Member of the General Partner and Investment Manager) EDGAR ↗
  • May 29, 2025 · D/A · $598,310,426 sold of Indefinite · 45 investors · min. $1 · role: Executive Officer, Promoter (Managing Member of the General Partner and Investment Manager) EDGAR ↗
  • Jun 3, 2024 · D/A · $524,160,426 sold of Indefinite · 40 investors · min. $1 · role: Executive Officer, Promoter (Managing Member of the General Partner and Investment Manager) EDGAR ↗
  • May 5, 2023 · D/A · $461,571,653 sold of Indefinite · 26 investors · min. $1,000,000 · role: Executive Officer, Promoter (Managing Member of the General Partner and Investment Manager) EDGAR ↗
  • May 19, 2022 · D/A · $449,571,653 sold of Indefinite · 22 investors · min. $1,000,000 · role: Executive Officer, Promoter (Managing Member of the General Partner and Investment Manager) EDGAR ↗
  • May 19, 2021 · D/A · $288,971,653 sold of Indefinite · 20 investors · min. $1,000,000 · role: Executive Officer, Promoter (Managing Member of the General Partner and Investment Manager) EDGAR ↗
  • Feb 28, 2020 · D/A · $53,571,653 sold of Indefinite · 8 investors · min. $1,000,000 · role: Executive Officer, Promoter (Managing Member of the General Partner and Promoter of the Issuer) EDGAR ↗
  • Mar 5, 2019 · D · $2,500,000 sold of Indefinite · 1 investors · min. $1,000,000 · role: Executive Officer, Promoter (Managing Member of the General Partner and Promoter of the Issuer) EDGAR ↗

Raised $667M from 52 investors as of the latest filing. Tomas is listed as executive officer, promoter on 8 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

PL
Pooled Investment Fund · group: Fairmount Healthcare

Paragon Laboratories L.P.

West Conshohocken, PA · Apr 3, 2026
  • Apr 3, 2026 · D · $0 sold of Indefinite · 0 investors · min. $1 · role: Executive Officer, Promoter (Managing Member of the General Partner and Investment Manager of the Issuer) EDGAR ↗

No sales reported yet as of the latest filing. Tomas is listed as executive officer, promoter.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FH
Pooled Investment Fund · group: Fairmount Healthcare

Fairmount Healthcare Co-Invest VI L.P.

West Conshohocken, PA · Mar 31, 2026
  • Mar 31, 2026 · D · $0 sold of Indefinite · 0 investors · min. $1 · role: Executive Officer, Promoter (Managing Member of the Member of the General Partner and Investment Manager of the Issuer) EDGAR ↗

No sales reported yet as of the latest filing. Tomas is listed as executive officer, promoter.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FH
Pooled Investment Fund · group: Fairmount Healthcare

Fairmount Healthcare Co-Invest V L.P.

West Conshohocken, PA · Nov 5, 2025
  • Nov 5, 2025 · D · $0 sold of Indefinite · 0 investors · min. $1 · role: Executive Officer, Promoter (Managing Member of the Member of the General Partner and Investment Manager of the Issuer) EDGAR ↗

No sales reported yet as of the latest filing. Tomas is listed as executive officer, promoter.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FH
Pooled Investment Fund · group: Fairmount Healthcare

Fairmount Healthcare Co-Invest IV L.P.

West Conshohocken, PA · Oct 31, 2024
  • Oct 31, 2024 · D · $0 sold of Indefinite · 0 investors · min. $1 · role: Executive Officer, Promoter (Managing Member of the Member of the General Partner and Investment Manager of the Issuer) EDGAR ↗

No sales reported yet as of the latest filing. Tomas is listed as executive officer, promoter.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

IB
Biotechnology

Interius BioTherapeutics, Inc.

Philadelphia, PA · May 27, 2021 → Jun 3, 2024 · 3 filings
  • Jun 3, 2024 · D · $51,432,536 sold of $82,509,197 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 20, 2023 · D · $21,451,331 sold of $21,451,331 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 27, 2021 · D · $43,625,657 sold of $76,344,951 · 25 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $51.4M from 25 investors (62% of the $82.5M target) as of the latest filing. Tomas is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

ZB
Biotechnology

Zenas BioPharma, Inc.

Waltham, MA · Nov 15, 2022 → May 14, 2024 · 2 filings
  • May 14, 2024 · D · $200,145,732 sold of $200,145,732 · 26 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 15, 2022 · D · $183,898,435 sold of $183,898,435 · 17 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $200.1M from 26 investors (100% of the $200.1M target) as of the latest filing. Tomas is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FH
Pooled Investment Fund · group: Fairmount Healthcare

Fairmount Healthcare Co-Invest III L.P.

West Conshohocken, PA · Mar 29, 2024
  • Mar 29, 2024 · D · $0 sold of Indefinite · 0 investors · min. $1 · role: Executive Officer, Promoter (Managing Member of the General Partner and Investment Manager of the Issuer) EDGAR ↗

No sales reported yet as of the latest filing. Tomas is listed as executive officer, promoter.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

ST
Biotechnology

Spyre Therapeutics, Inc.

Waltham, MA · Jul 6, 2023 → Dec 27, 2023 · 2 filings
  • Dec 27, 2023 · D · $180,000,000 sold of $180,000,000 · 30 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 6, 2023 · D · $210,000,248 sold of $210,000,248 · 41 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $210M from 54 investors (100% of the $180M target) as of the latest filing. Tomas is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FH
Pooled Investment Fund · group: Fairmount Healthcare

Fairmount Healthcare Co-Invest II L.P.

West Conshohocken, PA · Aug 21, 2023
  • Aug 21, 2023 · D · $15,173,000 sold of $15,173,000 · 14 investors · min. $1 · role: Executive Officer, Promoter (Managing Member of the General Partner and Investment Manager of the Issuer) EDGAR ↗

Raised $15.2M from 14 investors (100% of the $15.2M target) as of the latest filing. Tomas is listed as executive officer, promoter.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FH
Pooled Investment Fund · group: Fairmount Healthcare

Fairmount Healthcare Co-Invest L.P.

West Conshohocken, PA · Jun 30, 2023
  • Jun 30, 2023 · D · $25,000,000 sold of $25,000,000 · 18 investors · min. $1 · role: Executive Officer, Promoter (Managing Member of the General Partner and Investment Manager) EDGAR ↗

Raised $25M from 18 investors (100% of the $25M target) as of the latest filing. Tomas is listed as executive officer, promoter.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

DT
Biotechnology

Dianthus Therapeutics, Inc.

Waltham, MA · Jun 7, 2021 → Apr 21, 2022 · 2 filings
  • Apr 21, 2022 · D · $100,000,000 sold of $100,000,000 · 22 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 7, 2021 · D · $14,999,996 sold of $15,000,000 · 6 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $100M from 22 investors (100% of the $100M target) as of the latest filing. Tomas is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

MT
Biotechnology · group: Miragen Therapeutics

MIRAGEN THERAPEUTICS, INC.

Boulder, CO · Nov 6, 2020
  • Nov 6, 2020 · D · $90,997,328 sold of $90,997,328 · 22 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $91M from 22 investors (100% of the $91M target) as of the latest filing. Tomas is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FH
Pooled Investment Fund · group: Fairmount Healthcare

Fairmount Healthcare Fund L.P.

Philadelphia, PA · Oct 6, 2016 → Oct 27, 2020 · 5 filings
  • Oct 27, 2020 · D/A · $27,961,532 sold of Indefinite · 43 investors · min. $1,000,000 · role: Executive Officer, Promoter (Manager of the General Partner) EDGAR ↗
  • Nov 7, 2019 · D/A · $27,156,532 sold of Indefinite · 43 investors · min. $1,000,000 · role: Executive Officer, Promoter (Manager of the General Partner) EDGAR ↗
  • Nov 14, 2018 · D/A · $23,578,998 sold of Indefinite · 65 investors · min. $1,000,000 · role: Executive Officer, Promoter (Manager of the General Partner) EDGAR ↗
  • Oct 6, 2017 · D/A · $13,442,430 sold of Indefinite · 27 investors · min. $1,000,000 · role: Executive Officer, Promoter (Manager of the General Partner) EDGAR ↗
  • Oct 6, 2016 · D · $0 sold of Indefinite · 0 investors · min. $1,000,000 · role: Executive Officer, Promoter (Manager of the General Partner) EDGAR ↗

Raised $28M from 65 investors as of the latest filing. Tomas is listed as executive officer, promoter on 5 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FH
Pooled Investment Fund · group: Fairmount Healthcare

Fairmount Healthcare Feeder Fund Ltd.

Philadelphia, PA · Oct 6, 2016 → Oct 27, 2020 · 5 filings
  • Oct 27, 2020 · D/A · $3,634,510 sold of Indefinite · 6 investors · min. $1,000,000 · role: Executive Officer, Promoter EDGAR ↗
  • Nov 7, 2019 · D/A · $3,628,549 sold of Indefinite · 6 investors · min. $1,000,000 · role: Executive Officer, Promoter EDGAR ↗
  • Nov 14, 2018 · D/A · $3,573,549 sold of Indefinite · 8 investors · min. $1,000,000 · role: Executive Officer, Promoter EDGAR ↗
  • Oct 6, 2017 · D/A · $1,543,933 sold of Indefinite · 4 investors · min. $1,000,000 · role: Executive Officer, Promoter EDGAR ↗
  • Oct 6, 2016 · D · $0 sold of Indefinite · 0 investors · min. $1,000,000 · role: Executive Officer, Promoter EDGAR ↗

Raised $3.63M from 8 investors as of the latest filing. Tomas is listed as executive officer, promoter on 5 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

VT
Biotechnology · group: Fairmount Healthcare

Viridian Therapeutics, Inc.

Waltham, MA · May 8, 2020 → Sep 29, 2020 · 2 filings
  • Sep 29, 2020 · D · $27,000,000 sold of $27,000,000 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 8, 2020 · D · $2,000,000 sold of $5,000,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $27M from 9 investors (100% of the $27M target) as of the latest filing. Tomas is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

V
Biotechnology · group: Fairmount Healthcare

Viridian, LLC

Philadelphia, PA · Dec 13, 2018
  • Dec 13, 2018 · D · $1,150,000 sold of $3,000,000 · 1 investors · min. No minimum reported · role: Executive Officer (Manager) EDGAR ↗

Raised $1.15M from 1 investor (38% of the $3M target) as of the latest filing. Tomas is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

QB
Biotechnology

Quellis Biosciences, Inc.

Waltham, MA · Jun 1, 2018 → Dec 11, 2018 · 2 filings
  • Dec 11, 2018 · D · $2,500,000 sold of $18,518,047 · 1 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jun 1, 2018 · D · $0 sold of Indefinite · 1 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗

Raised $12.1M from 3 investors (65% of the $18.5M target) as of the latest filing. Tomas is listed as executive officer, director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

People around Tomas 40

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.

FF
Management entity

Fairmount Funds Management LLC

Executive Officer · 21 shared filings (10 issuers)

Fairmount Funds Management LLC is on 10 issuers in total — a repeat sponsor. Their page lists every one.

FH
Management entity

Fairmount Healthcare Fund II GP LLC

Executive Officer, Promoter · 12 shared filings (2 issuers)

Listed on the same filings as Tomas Kiselak. Their page shows their other deals.

PL
Management entity

Paragon Labs GP LLC

Executive Officer, Promoter · 1 shared filing (1 issuer)

Listed on the same filings as Tomas Kiselak. Their page shows their other deals.

PH
No photo found yet (own website and image search run after this page is viewed)
Person

Peter Harwin

Executive Officer, Promoter, Director · 43 shared filings (17 issuers) · also on 3 other issuers

Peter Harwin is on 20 issuers in total — a repeat sponsor. Their page lists every one.

LM
No photo found yet (own website and image search run after this page is viewed)
Person

Leon O. Moulder, Jr.

Director, Executive Officer · 7 shared filings (3 issuers) · also on 4 other issuers

Leon O. Moulder, Jr. is on 7 issuers in total — a repeat sponsor. Their page lists every one.

JV
No photo found yet (own website and image search run after this page is viewed)
Person

Jonathan Violin

Executive Officer, Director · 6 shared filings (4 issuers) · also on 2 other issuers

Jonathan Violin is on 6 issuers in total — a repeat sponsor. Their page lists every one.

DM
No photo found yet (own website and image search run after this page is viewed)
Person

Dora Mitchell

Executive Officer · 3 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Tomas Kiselak. Their page shows their other deals.

AL
No photo found yet (own website and image search run after this page is viewed)
Person

Alison Lawton

Director · 2 shared filings (1 issuer) · also on 4 other issuers

Alison Lawton is on 5 issuers in total — a repeat sponsor. Their page lists every one.

HL
No photo found yet (own website and image search run after this page is viewed)
Person

Hongbo Lu

Director · 2 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Tomas Kiselak. Their page shows their other deals.

KT
No photo found yet (own website and image search run after this page is viewed)
Person

Kenneth Evan Thompson

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Tomas Kiselak. Their page shows their other deals.

BL
No photo found yet (own website and image search run after this page is viewed)
Person

Benjamin Lund

Director · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Tomas Kiselak. Their page shows their other deals.

PD
No photo found yet (own website and image search run after this page is viewed)
Person

Philip R. Johnson, M.D.

Executive Officer, Director · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Tomas Kiselak. Their page shows their other deals.

JB
No photo found yet (own website and image search run after this page is viewed)
Person

JAMES PATRICK BOYLAN

Director · 2 shared filings (1 issuer)

Listed on the same filings as Tomas Kiselak. Their page shows their other deals.

JO
No photo found yet (own website and image search run after this page is viewed)
Person

JOHN JACOB ORLOFF

Director · 2 shared filings (1 issuer)

Listed on the same filings as Tomas Kiselak. Their page shows their other deals.

MH
No photo found yet (own website and image search run after this page is viewed)
Person

Michael Henderson

Director · 2 shared filings (1 issuer)

Listed on the same filings as Tomas Kiselak. Their page shows their other deals.

CT
No photo found yet (own website and image search run after this page is viewed)
Person

Cameron Turtle

Executive Officer, Director · 2 shared filings (1 issuer)

Listed on the same filings as Tomas Kiselak. Their page shows their other deals.

RC
No photo found yet (own website and image search run after this page is viewed)
Person

Russell J. Cox

Director · 2 shared filings (1 issuer)

Listed on the same filings as Tomas Kiselak. Their page shows their other deals.

JF
No photo found yet (own website and image search run after this page is viewed)
Person

Joseph Farmer

Executive Officer · 2 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Tomas Kiselak. Their page shows their other deals.

PE
No photo found yet (own website and image search run after this page is viewed)
Person

PATRICK GERALD ENRIGHT

Director · 2 shared filings (1 issuer)

Listed on the same filings as Tomas Kiselak. Their page shows their other deals.

LR
No photo found yet (own website and image search run after this page is viewed)
Person

Lee Rauch

Executive Officer, Director · 1 shared filing (1 issuer) · also on 2 other issuers

Listed on the same filings as Tomas Kiselak. Their page shows their other deals.

JN
No photo found yet (own website and image search run after this page is viewed)
Person

Jake Nunn

Director · 1 shared filing (1 issuer) · also on 1 other issuer

Listed on the same filings as Tomas Kiselak. Their page shows their other deals.

AM
No photo found yet (own website and image search run after this page is viewed)
Person

Arlene Morris

Director · 1 shared filing (1 issuer) · also on 4 other issuers

Arlene Morris is on 5 issuers in total — a repeat sponsor. Their page lists every one.

JA
No photo found yet (own website and image search run after this page is viewed)
Person

Jeffrey Albers

Director · 1 shared filing (1 issuer) · also on 4 other issuers

Jeffrey Albers is on 5 issuers in total — a repeat sponsor. Their page lists every one.

PS
No photo found yet (own website and image search run after this page is viewed)
Person

Paula Soteropoulos

Director · 1 shared filing (1 issuer) · also on 3 other issuers

Listed on the same filings as Tomas Kiselak. Their page shows their other deals.

PA
No photo found yet (own website and image search run after this page is viewed)
Person

Patricia L. Allen

Director · 1 shared filing (1 issuer) · also on 4 other issuers

Patricia L. Allen is on 5 issuers in total — a repeat sponsor. Their page lists every one.

JH
No photo found yet (own website and image search run after this page is viewed)
Person

Jeffrey S. Hatfield

Director · 1 shared filing (1 issuer)

Listed on the same filings as Tomas Kiselak. Their page shows their other deals.

CG
No photo found yet (own website and image search run after this page is viewed)
Person

Chris Garabedian

Director · 1 shared filing (1 issuer) · also on 11 other issuers

Chris Garabedian is on 12 issuers in total — a repeat sponsor. Their page lists every one.

FC
No photo found yet (own website and image search run after this page is viewed)
Person

Fred Callori

Director · 1 shared filing (1 issuer) · also on 4 other issuers

Fred Callori is on 5 issuers in total — a repeat sponsor. Their page lists every one.

CG
No photo found yet (own website and image search run after this page is viewed)
Person

Christopher Garabedian

Director · 1 shared filing (1 issuer)

Listed on the same filings as Tomas Kiselak. Their page shows their other deals.

TX
No photo found yet (own website and image search run after this page is viewed)
Person

Tim Xiao

Director · 1 shared filing (1 issuer) · also on 1 other issuer

Listed on the same filings as Tomas Kiselak. Their page shows their other deals.

PJ
No photo found yet (own website and image search run after this page is viewed)
Person

Philip R. Johnson

Executive Officer, Director · 1 shared filing (1 issuer) · also on 1 other issuer

Listed on the same filings as Tomas Kiselak. Their page shows their other deals.

The team behind the deals

FH
Sponsor group

Fairmount Healthcare

15 issuers · 39 filings · $1.85B reported sold · 2016–2026

One team, 15 deal companies. Tomas Kiselak is listed on 14 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Tomas Kiselak.

MT
Sponsor group

Miragen Therapeutics

2 issuers · 13 filings · $131.7M reported sold · 2009–2020

One team, 2 deal companies. Tomas Kiselak is listed on 1 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Tomas Kiselak.

Same business address

43 other issuers file from the same address

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Business registration (state registry / Secretary of State)

Individuals are not matched to business registrations — registries list companies, and a name alone is not enough to tie a person to one. Officers and managers appear by name inside each matched company's record on the issuer pages. Registries searched: AL (Alabama Secretary of State — Business Entity Records (arc-sos.state.al.us), searched by issuer name, data as of Oct 24, 2026); CO (Colorado Secretary of State — Business Entities in Colorado (data.colorado.gov), data as of Oct 23, 2026); CT (Connecticut Secretary of the State — Business Registry (data.ct.gov), data as of Oct 24, 2026); FL (Florida Department of State, Division of Corporations — quarterly corporate data file (Sunbiz), data as of Oct 7, 2026); NY (New York Department of State — Corporations and Other Entities (data.ny.gov: All Filings + Active Corporations), data as of Oct 20, 2026); OR (Oregon Secretary of State — Active Businesses, All (data.oregon.gov), data as of Oct 20, 2026); PA (Pennsylvania Department of State — Registered Businesses, Current (data.pa.gov), data as of Oct 6, 2026); TX (Texas Comptroller — Active Franchise Taxpayers incl. Secretary of State file data (data.texas.gov), data as of Oct 24, 2026). Registries of other states have not been searched: many publish no bulk file and require a CAPTCHA or bot challenge on their search page, which we do not bypass (Delaware, for example, offers no public bulk file).

Adviser registration (Form ADV)

A person is never an adviser firm. 10 of the 20 issuers this person is listed on match a Form ADV adviser (searched 24,962 advisers as of Oct 2, 2026): Fairmount Healthcare Co-Invest VII L.P., Fairmount Healthcare Fund II L.P., Fairmount Healthcare Feeder Fund II L.P., Paragon Laboratories L.P., Fairmount Healthcare Co-Invest VI L.P., Fairmount Healthcare Co-Invest V L.P., Fairmount Healthcare Co-Invest IV L.P., Fairmount Healthcare Co-Invest III L.P., Fairmount Healthcare Co-Invest II L.P., Fairmount Healthcare Co-Invest L.P..

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to Tomas Kiselak by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 20 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers Tomas Kiselak is listed on: none on file. No website or social profile named in Spyre Therapeutics, Inc.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #109,717 of 374,652 in line (1,386 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Waltham, MA). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn people search ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗Pennsylvania UJS portal case search ↗Massachusetts MassCourts ↗Colorado state courts — find the court ↗Texas re:SearchTX court records ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

Pennsylvania Secretary of State business search ↗Massachusetts Secretary of State business search ↗Colorado Secretary of State business search ↗Texas Secretary of State business search ↗OpenCorporates ↗

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Tomas Kiselak appears on a new Form D, or when a court case or SEC action is matched to them. See plans →